Загрузка...
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
PURPOSE: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-...
Сохранить в:
| Опубликовано в: : | Clin Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497957/ https://ncbi.nlm.nih.gov/pubmed/25823918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.02.018 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|